{
    "info": {
        "nct_id": "NCT04312841",
        "official_title": "Letermovir for Cytomegalovirus Prophylaxis in Patients With Hematological Malignancies Treated With Alemtuzumab",
        "inclusion_criteria": "* Confirmed diagnosis of T-cell or B-cell prolymphocytic leukemia, chronic lymphocytic leukemia, peripheral T-cell lymphoma, cutaneous T-cell lymphoma, or Sezary syndrome\n* Intent to treat with alemtuzumab. Monotherapy or combination with chemotherapy is allowed\n* Confirmed seropositivity for CMV IgG (>= 0.7 U/mL) within 1 year of first letermovir dose\n* Confirmed lack of active CMV infection as evidenced by:\n\n  * Undetectable CMV deoxyribonucleic acid (DNA) by Abbott RealTime CMV in vitro polymerase chain reaction assay (< 50 IU/mL) within 7 days of first letermovir dose AND\n  * Negative CMV IgM (< 30 AU/mL) within 7 days of first letermovir dose\n* Able to provide informed consent\n* Life expectancy > 4 months\n* Eastern Cooperative Oncology Group (ECOG) performance status =< 3\n* Highly unlikely to become pregnant or impregnate a partner by meeting at least one of the following:\n\n  * A female subject who is not of reproductive potential is eligible without requiring the use of contraception. A female subject who is not of reproductive potential is defined as one who:\n\n    * Has reached natural menopause (defined as 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone [FSH] levels in the postmenopausal range as determined by the local laboratory, or 12 months of spontaneous amenorrhea) OR\n    * Is 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy OR\n    * Has undergone bilateral tubal ligation. Spontaneous amenorrhea does not include cases for which there is an underlying disease that causes amenorrhea (e.g., anorexia nervosa)\n  * A male subject who is not of reproductive potential is eligible without requiring the use of contraception. A male subject who is not of reproductive potential is defined as one whom has undergone a successful defined as:\n\n    * Microscopic documentation of azoospermia OR\n    * A vasectomy more than 2 years ago with no resultant pregnancy despite sexual activity post-vasectomy\n  * A male or female subject who is of reproductive potential agrees to true abstinence or to use (or have their partner use) an acceptable method of birth control starting from the time of consent through 90 days after the last dose of study therapy. True abstinence is defined as abstinence in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., abstinence only on certain calendar days, abstinence only during ovulation period, use of symptothermal method, use of post-ovulation methods) and withdrawal are not acceptable methods of contraception. Acceptable methods of birth control are:\n\n    * Intrauterine device (IUD), diaphragm with spermicide, contraceptive sponge, condom, and vasectomy OR use of appropriate double barrier contraception. Hormonal contraceptives (e.g., birth control pills, transdermal patch, or injectables) are also acceptable\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* History of confirmed CMV disease within 1 year of study entry\n* History of prior allogeneic hematopoietic stem cell transplant\n* End stage renal disease with creatinine clearance < 10 mL/min as defined by Cockcroft-Gault equation using serum creatinine within 7 days of enrollment\n* Child-Pugh class C within 7 days of enrollment\n* Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 5 times the upper limit of normal (ULN) or serum total bilirubin > 2.5 x ULN\n\n  * Note: Subjects who meet this exclusion criterion may, at the discretion of the investigator, have one repeat testing done. If the repeat value does not meet this criterion, they may continue in the screening process. Only the specific out of range value should be repeated (not the entire panel)\n* Both moderate hepatic insufficiency AND moderate renal insufficiency:\n\n  * Moderate hepatic insufficiency is defined as Child Pugh Class B\n  * Moderate renal insufficiency is defined as a creatinine clearance less than 50 mL/min, as calculated by the Cockcroft-Gault equation\n* Cytopenias are NOT an exclusion criteria in this trial as cytopenias are common in this patient population and letermovir has no known adverse effects on blood counts. Patients will be treated per institutional standard of care with as needed transfusions and growth factor support\n* Received any of the following drugs within 7 days of enrollment or plans to receive any of the following during the study:\n\n  * Ganciclovir\n  * Valganciclovir\n  * Foscarnet\n  * Acyclovir (at doses > 3200 mg PO per day or > 25 mg/kg IV per day)\n  * Valacyclovir (at doses > 3000 mg PO per day)\n  * Famciclovir (at doses > 1500 mg PO per day)\n  * Cyclosporine A\n  * Pimozide\n  * Ergot alkaloids (ergotamine and dihydroergotamine)\n  * Atorvastatin at doses greater than 20 mg daily\n* Received any of the following within 30 days prior to enrollment\n\n  * Cidofovir\n  * CMV hyper-immune globulin\n  * Any investigational CMV antiviral agent/biologic therapy\n* Infection or underlying disease necessitating ongoing use of prohibited medications\n* Suspected or known hypersensitivity to active or inactive ingredients of letermovir formulations\n* Positive at the time of screening for:\n\n  * Human immunodeficiency virus (HIV) with CD4 count < 350. If HIV positive, must remain on antiretroviral therapy that is not anticipated to interact with letermovir throughout study\n  * Hepatitis B surface antigen or core antibody positivity associated with detectable viral load. For any patient with serologic evidence of prior infection but undetectable viral load, viral load and surface antigen will be monitored every 2 weeks. Those with evidence of reactivation (detectable viral load) will be treated with entecavir or lamivudine. Upon resolution of detectable viral load, the patient will be allowed to continue on trial assuming adequate liver function as defined above. Alternatively, patients may be put on prophylactic entecavir or lamivudine to prevent hepatitis B reactivation at the investigator's discretion\n  * Hepatitis C if no prior or current curative antiviral therapy. For those currently on curative antiviral therapy, they will be allowed on trial if hepatitis C virus (HCV) quantitation is below the limit of detection and adequate liver function as above\n* Pregnant or expecting to conceive, is breastfeeding, or plans to breastfeed from the time of consent through 90 days after the last dose of study therapy\n* Expecting to donate eggs or sperm starting from the time of consent through 90 days after the last dose of study therapy\n* Currently participating or has participated in a study with an unapproved investigational compound or device within 28 days, or 5X half-life of the investigational compound (excluding monoclonal antibodies), whichever is longer, of initial dosing on this study. Subjects previously treated with a monoclonal antibody will be eligible to participate after a 28-day washout period\n* Previous participation in a study using letermovir\n* Has a history or current evidence of any condition, therapy, lab abnormality, or other circumstance that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or would be put at undue risk as judged by the investigator, such that it is not in the best interest of the subject to participate in this study",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "* A female subject who is not of reproductive potential is eligible without requiring the use of contraception. A female subject who is not of reproductive potential is defined as one who:",
                "criterions": [
                    {
                        "exact_snippets": "A female subject who is not of reproductive potential is eligible without requiring the use of contraception.",
                        "criterion": "reproductive potential (female subject)",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "not of reproductive potential"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "A female subject who is not of reproductive potential is eligible without requiring the use of contraception.",
                        "criterion": "reproductive potential (female subject)",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "not of reproductive potential"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Undetectable CMV deoxyribonucleic acid (DNA) by Abbott RealTime CMV in vitro polymerase chain reaction assay (< 50 IU/mL) within 7 days of first letermovir dose AND",
                "criterions": [
                    {
                        "exact_snippets": "Undetectable CMV deoxyribonucleic acid (DNA) by Abbott RealTime CMV in vitro polymerase chain reaction assay (< 50 IU/mL) within 7 days of first letermovir dose",
                        "criterion": "CMV DNA level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "IU/mL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Undetectable CMV deoxyribonucleic acid (DNA) by Abbott RealTime CMV in vitro polymerase chain reaction assay (< 50 IU/mL) within 7 days of first letermovir dose",
                        "criterion": "CMV DNA level",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "within 7 days of first letermovir dose"
                        }
                    },
                    {
                        "exact_snippets": "Undetectable CMV deoxyribonucleic acid (DNA) by Abbott RealTime CMV in vitro polymerase chain reaction assay (< 50 IU/mL) within 7 days of first letermovir dose",
                        "criterion": "CMV DNA level",
                        "requirement": {
                            "requirement_type": "detection_method",
                            "expected_value": "Abbott RealTime CMV in vitro polymerase chain reaction assay"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Undetectable CMV deoxyribonucleic acid (DNA) by Abbott RealTime CMV in vitro polymerase chain reaction assay (< 50 IU/mL) within 7 days of first letermovir dose",
                        "criterion": "CMV DNA level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "IU/mL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Undetectable CMV deoxyribonucleic acid (DNA) by Abbott RealTime CMV in vitro polymerase chain reaction assay (< 50 IU/mL) within 7 days of first letermovir dose",
                        "criterion": "CMV DNA level",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "within 7 days of first letermovir dose"
                        }
                    },
                    {
                        "exact_snippets": "Undetectable CMV deoxyribonucleic acid (DNA) by Abbott RealTime CMV in vitro polymerase chain reaction assay (< 50 IU/mL) within 7 days of first letermovir dose",
                        "criterion": "CMV DNA level",
                        "requirement": {
                            "requirement_type": "detection_method",
                            "expected_value": "Abbott RealTime CMV in vitro polymerase chain reaction assay"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* A vasectomy more than 2 years ago with no resultant pregnancy despite sexual activity post-vasectomy",
                "criterions": [
                    {
                        "exact_snippets": "A vasectomy more than 2 years ago",
                        "criterion": "vasectomy",
                        "requirement": {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "no resultant pregnancy despite sexual activity post-vasectomy",
                        "criterion": "pregnancy after vasectomy",
                        "requirement": {
                            "requirement_type": "occurrence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "A vasectomy more than 2 years ago",
                        "criterion": "vasectomy",
                        "requirement": {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "no resultant pregnancy despite sexual activity post-vasectomy",
                        "criterion": "pregnancy after vasectomy",
                        "requirement": {
                            "requirement_type": "occurrence",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* A male subject who is not of reproductive potential is eligible without requiring the use of contraception. A male subject who is not of reproductive potential is defined as one whom has undergone a successful defined as:",
                "criterions": [
                    {
                        "exact_snippets": "A male subject who is not of reproductive potential is eligible",
                        "criterion": "reproductive potential (male)",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "not of reproductive potential"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "A male subject who is not of reproductive potential is eligible",
                        "criterion": "reproductive potential (male)",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "not of reproductive potential"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Has undergone bilateral tubal ligation. Spontaneous amenorrhea does not include cases for which there is an underlying disease that causes amenorrhea (e.g., anorexia nervosa)",
                "criterions": [
                    {
                        "exact_snippets": "Has undergone bilateral tubal ligation",
                        "criterion": "bilateral tubal ligation",
                        "requirement": {
                            "requirement_type": "history of procedure",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Spontaneous amenorrhea does not include cases for which there is an underlying disease that causes amenorrhea (e.g., anorexia nervosa)",
                        "criterion": "spontaneous amenorrhea",
                        "requirement": {
                            "requirement_type": "cause",
                            "expected_value": "not due to underlying disease (e.g., anorexia nervosa)"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Has undergone bilateral tubal ligation",
                        "criterion": "bilateral tubal ligation",
                        "requirement": {
                            "requirement_type": "history of procedure",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Spontaneous amenorrhea does not include cases for which there is an underlying disease that causes amenorrhea (e.g., anorexia nervosa)",
                        "criterion": "spontaneous amenorrhea",
                        "requirement": {
                            "requirement_type": "cause",
                            "expected_value": "not due to underlying disease (e.g., anorexia nervosa)"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "* Ganciclovir",
                "criterions": [
                    {
                        "exact_snippets": "Ganciclovir",
                        "criterion": "Ganciclovir",
                        "requirement": {
                            "requirement_type": "exposure or use",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Ganciclovir",
                        "criterion": "Ganciclovir",
                        "requirement": {
                            "requirement_type": "exposure or use",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Foscarnet",
                "criterions": [
                    {
                        "exact_snippets": "Foscarnet",
                        "criterion": "Foscarnet administration",
                        "requirement": {
                            "requirement_type": "administration",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Foscarnet",
                    "criterion": "Foscarnet administration",
                    "requirement": {
                        "requirement_type": "administration",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Pimozide",
                "criterions": [
                    {
                        "exact_snippets": "Pimozide",
                        "criterion": "pimozide use",
                        "requirement": {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Pimozide",
                    "criterion": "pimozide use",
                    "requirement": {
                        "requirement_type": "use",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Cidofovir",
                "criterions": [
                    {
                        "exact_snippets": "Cidofovir",
                        "criterion": "Cidofovir",
                        "requirement": {
                            "requirement_type": "exposure or use",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Cidofovir",
                    "criterion": "Cidofovir",
                    "requirement": {
                        "requirement_type": "exposure or use",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Positive at the time of screening for:",
                "criterions": [
                    {
                        "exact_snippets": "Positive at the time of screening for:",
                        "criterion": "screening test result",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": "positive"
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Positive at the time of screening for:",
                    "criterion": "screening test result",
                    "requirement": {
                        "requirement_type": "result",
                        "expected_value": "positive"
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* CMV hyper-immune globulin",
                "criterions": [
                    {
                        "exact_snippets": "CMV hyper-immune globulin",
                        "criterion": "CMV hyper-immune globulin",
                        "requirement": {
                            "requirement_type": "exposure or administration",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "CMV hyper-immune globulin",
                    "criterion": "CMV hyper-immune globulin",
                    "requirement": {
                        "requirement_type": "exposure or administration",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Valganciclovir",
                "criterions": [
                    {
                        "exact_snippets": "Valganciclovir",
                        "criterion": "valganciclovir use",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Valganciclovir",
                    "criterion": "valganciclovir use",
                    "requirement": {
                        "requirement_type": "presence",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Ergot alkaloids (ergotamine and dihydroergotamine)",
                "criterions": [
                    {
                        "exact_snippets": "Ergot alkaloids (ergotamine and dihydroergotamine)",
                        "criterion": "ergot alkaloids (ergotamine and dihydroergotamine)",
                        "requirement": {
                            "requirement_type": "exposure/use",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Ergot alkaloids (ergotamine and dihydroergotamine)",
                    "criterion": "ergot alkaloids (ergotamine and dihydroergotamine)",
                    "requirement": {
                        "requirement_type": "exposure/use",
                        "expected_value": false
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Cyclosporine A",
                "criterions": [
                    {
                        "exact_snippets": "Cyclosporine A",
                        "criterion": "Cyclosporine A",
                        "requirement": {
                            "requirement_type": "exposure or use",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Cyclosporine A",
                        "criterion": "Cyclosporine A",
                        "requirement": {
                            "requirement_type": "exposure or use",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Cytopenias are NOT an exclusion criteria in this trial as cytopenias are common in this patient population and letermovir has no known adverse effects on blood counts. Patients will be treated per institutional standard of care with as needed transfusions and growth factor support",
                "criterions": [
                    {
                        "exact_snippets": "Cytopenias are NOT an exclusion criteria in this trial",
                        "criterion": "cytopenias",
                        "requirement": {
                            "requirement_type": "exclusion",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Cytopenias are NOT an exclusion criteria in this trial",
                        "criterion": "cytopenias",
                        "requirement": {
                            "requirement_type": "exclusion",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Any investigational CMV antiviral agent/biologic therapy",
                "criterions": [
                    {
                        "exact_snippets": "Any investigational CMV antiviral agent/biologic therapy",
                        "criterion": "investigational CMV antiviral agent/biologic therapy",
                        "requirement": {
                            "requirement_type": "use or exposure",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Any investigational CMV antiviral agent/biologic therapy",
                        "criterion": "investigational CMV antiviral agent/biologic therapy",
                        "requirement": {
                            "requirement_type": "use or exposure",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Child-Pugh class C within 7 days of enrollment",
                "criterions": [
                    {
                        "exact_snippets": "Child-Pugh class C within 7 days of enrollment",
                        "criterion": "Child-Pugh class",
                        "requirement": {
                            "requirement_type": "classification",
                            "expected_value": "C"
                        }
                    },
                    {
                        "exact_snippets": "Child-Pugh class C within 7 days of enrollment",
                        "criterion": "Child-Pugh class",
                        "requirement": {
                            "requirement_type": "timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days from enrollment"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Child-Pugh class C within 7 days of enrollment",
                                "criterion": "Child-Pugh class",
                                "requirement": {
                                    "requirement_type": "classification",
                                    "expected_value": "C"
                                }
                            },
                            {
                                "exact_snippets": "Child-Pugh class C within 7 days of enrollment",
                                "criterion": "Child-Pugh class",
                                "requirement": {
                                    "requirement_type": "timeframe",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 7,
                                        "unit": "days from enrollment"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* History of confirmed CMV disease within 1 year of study entry",
                "criterions": [
                    {
                        "exact_snippets": "History of confirmed CMV disease within 1 year of study entry",
                        "criterion": "CMV disease",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "History of confirmed CMV disease within 1 year of study entry",
                        "criterion": "CMV disease",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Atorvastatin at doses greater than 20 mg daily",
                "criterions": [
                    {
                        "exact_snippets": "Atorvastatin at doses greater than 20 mg daily",
                        "criterion": "atorvastatin dose",
                        "requirement": {
                            "requirement_type": "dosage",
                            "expected_value": {
                                "operator": ">",
                                "value": 20,
                                "unit": "mg daily"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Atorvastatin at doses greater than 20 mg daily",
                        "criterion": "atorvastatin dose",
                        "requirement": {
                            "requirement_type": "dosage",
                            "expected_value": {
                                "operator": ">",
                                "value": 20,
                                "unit": "mg daily"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Moderate renal insufficiency is defined as a creatinine clearance less than 50 mL/min, as calculated by the Cockcroft-Gault equation",
                "criterions": [
                    {
                        "exact_snippets": "creatinine clearance less than 50 mL/min, as calculated by the Cockcroft-Gault equation",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "mL/min"
                            }
                        }
                    },
                    {
                        "exact_snippets": "creatinine clearance less than 50 mL/min, as calculated by the Cockcroft-Gault equation",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft-Gault equation"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "creatinine clearance less than 50 mL/min, as calculated by the Cockcroft-Gault equation",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "mL/min"
                            }
                        }
                    },
                    {
                        "exact_snippets": "creatinine clearance less than 50 mL/min, as calculated by the Cockcroft-Gault equation",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft-Gault equation"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Received any of the following drugs within 7 days of enrollment or plans to receive any of the following during the study:",
                "criterions": [
                    {
                        "exact_snippets": "Received any of the following drugs within 7 days of enrollment",
                        "criterion": "receipt of specified drugs",
                        "requirement": {
                            "requirement_type": "time since last dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Received any of the following drugs within 7 days of enrollment",
                        "criterion": "receipt of specified drugs",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "plans to receive any of the following during the study",
                        "criterion": "planned receipt of specified drugs",
                        "requirement": {
                            "requirement_type": "planned administration during study",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Received any of the following drugs within 7 days of enrollment",
                                "criterion": "receipt of specified drugs",
                                "requirement": {
                                    "requirement_type": "time since last dose",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 7,
                                        "unit": "days"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Received any of the following drugs within 7 days of enrollment",
                                "criterion": "receipt of specified drugs",
                                "requirement": {
                                    "requirement_type": "status",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "plans to receive any of the following during the study",
                        "criterion": "planned receipt of specified drugs",
                        "requirement": {
                            "requirement_type": "planned administration during study",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Moderate hepatic insufficiency is defined as Child Pugh Class B",
                "criterions": [
                    {
                        "exact_snippets": "Moderate hepatic insufficiency is defined as Child Pugh Class B",
                        "criterion": "hepatic insufficiency",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "moderate"
                        }
                    },
                    {
                        "exact_snippets": "Child Pugh Class B",
                        "criterion": "Child Pugh classification",
                        "requirement": {
                            "requirement_type": "class",
                            "expected_value": "B"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Moderate hepatic insufficiency is defined as Child Pugh Class B",
                        "criterion": "hepatic insufficiency",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "moderate"
                        }
                    },
                    {
                        "exact_snippets": "Child Pugh Class B",
                        "criterion": "Child Pugh classification",
                        "requirement": {
                            "requirement_type": "class",
                            "expected_value": "B"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Acyclovir (at doses > 3200 mg PO per day or > 25 mg/kg IV per day)",
                "criterions": [
                    {
                        "exact_snippets": "Acyclovir (at doses > 3200 mg PO per day or > 25 mg/kg IV per day)",
                        "criterion": "acyclovir dose",
                        "requirement": {
                            "requirement_type": "dose",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">",
                                        "value": 3200,
                                        "unit": "mg PO per day"
                                    },
                                    {
                                        "operator": ">",
                                        "value": 25,
                                        "unit": "mg/kg IV per day"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Acyclovir (at doses > 3200 mg PO per day or > 25 mg/kg IV per day)",
                        "criterion": "acyclovir dose",
                        "requirement": {
                            "requirement_type": "dose",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">",
                                        "value": 3200,
                                        "unit": "mg PO per day"
                                    },
                                    {
                                        "operator": ">",
                                        "value": 25,
                                        "unit": "mg/kg IV per day"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Infection or underlying disease necessitating ongoing use of prohibited medications",
                "criterions": [
                    {
                        "exact_snippets": "Infection or underlying disease necessitating ongoing use of prohibited medications",
                        "criterion": "infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Infection or underlying disease necessitating ongoing use of prohibited medications",
                        "criterion": "infection",
                        "requirement": {
                            "requirement_type": "necessitates ongoing use of prohibited medications",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Infection or underlying disease necessitating ongoing use of prohibited medications",
                        "criterion": "underlying disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Infection or underlying disease necessitating ongoing use of prohibited medications",
                        "criterion": "underlying disease",
                        "requirement": {
                            "requirement_type": "necessitates ongoing use of prohibited medications",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Infection or underlying disease necessitating ongoing use of prohibited medications",
                                "criterion": "infection",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Infection or underlying disease necessitating ongoing use of prohibited medications",
                                "criterion": "infection",
                                "requirement": {
                                    "requirement_type": "necessitates ongoing use of prohibited medications",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Infection or underlying disease necessitating ongoing use of prohibited medications",
                                "criterion": "underlying disease",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Infection or underlying disease necessitating ongoing use of prohibited medications",
                                "criterion": "underlying disease",
                                "requirement": {
                                    "requirement_type": "necessitates ongoing use of prohibited medications",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Expecting to donate eggs or sperm starting from the time of consent through 90 days after the last dose of study therapy",
                "criterions": [
                    {
                        "exact_snippets": "Expecting to donate eggs or sperm starting from the time of consent through 90 days after the last dose of study therapy",
                        "criterion": "expectation to donate eggs or sperm",
                        "requirement": {
                            "requirement_type": "expectation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Expecting to donate eggs or sperm starting from the time of consent through 90 days after the last dose of study therapy",
                        "criterion": "expectation to donate eggs or sperm",
                        "requirement": {
                            "requirement_type": "time period",
                            "expected_value": "from the time of consent through 90 days after the last dose of study therapy"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Expecting to donate eggs or sperm starting from the time of consent through 90 days after the last dose of study therapy",
                        "criterion": "expectation to donate eggs or sperm",
                        "requirement": {
                            "requirement_type": "expectation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Expecting to donate eggs or sperm starting from the time of consent through 90 days after the last dose of study therapy",
                        "criterion": "expectation to donate eggs or sperm",
                        "requirement": {
                            "requirement_type": "time period",
                            "expected_value": "from the time of consent through 90 days after the last dose of study therapy"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* End stage renal disease with creatinine clearance < 10 mL/min as defined by Cockcroft-Gault equation using serum creatinine within 7 days of enrollment",
                "criterions": [
                    {
                        "exact_snippets": "End stage renal disease",
                        "criterion": "renal disease stage",
                        "requirement": {
                            "requirement_type": "stage",
                            "expected_value": "end stage"
                        }
                    },
                    {
                        "exact_snippets": "creatinine clearance < 10 mL/min as defined by Cockcroft-Gault equation",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 10,
                                "unit": "mL/min"
                            }
                        }
                    },
                    {
                        "exact_snippets": "creatinine clearance < 10 mL/min as defined by Cockcroft-Gault equation",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft-Gault equation"
                        }
                    },
                    {
                        "exact_snippets": "serum creatinine within 7 days of enrollment",
                        "criterion": "serum creatinine measurement timing",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": "within 7 days of enrollment"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "End stage renal disease",
                        "criterion": "renal disease stage",
                        "requirement": {
                            "requirement_type": "stage",
                            "expected_value": "end stage"
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "creatinine clearance < 10 mL/min as defined by Cockcroft-Gault equation",
                                "criterion": "creatinine clearance",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": "<",
                                        "value": 10,
                                        "unit": "mL/min"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "creatinine clearance < 10 mL/min as defined by Cockcroft-Gault equation",
                                "criterion": "creatinine clearance",
                                "requirement": {
                                    "requirement_type": "calculation method",
                                    "expected_value": "Cockcroft-Gault equation"
                                }
                            },
                            {
                                "exact_snippets": "serum creatinine within 7 days of enrollment",
                                "criterion": "serum creatinine measurement timing",
                                "requirement": {
                                    "requirement_type": "time window",
                                    "expected_value": "within 7 days of enrollment"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Pregnant or expecting to conceive, is breastfeeding, or plans to breastfeed from the time of consent through 90 days after the last dose of study therapy",
                "criterions": [
                    {
                        "exact_snippets": "Pregnant or expecting to conceive",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "pregnancy",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Pregnant or expecting to conceive",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "expecting to conceive",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "is breastfeeding",
                        "criterion": "breastfeeding status",
                        "requirement": {
                            "requirement_type": "breastfeeding",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "plans to breastfeed from the time of consent through 90 days after the last dose of study therapy",
                        "criterion": "future breastfeeding plans",
                        "requirement": {
                            "requirement_type": "plans to breastfeed",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "plans to breastfeed from the time of consent through 90 days after the last dose of study therapy",
                        "criterion": "future breastfeeding plans",
                        "requirement": {
                            "requirement_type": "time period",
                            "expected_value": "from the time of consent through 90 days after the last dose of study therapy"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "not_criteria": {
                            "exact_snippets": "Pregnant or expecting to conceive",
                            "criterion": "pregnancy status",
                            "requirement": {
                                "requirement_type": "pregnancy",
                                "expected_value": false
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "Pregnant or expecting to conceive",
                            "criterion": "pregnancy status",
                            "requirement": {
                                "requirement_type": "expecting to conceive",
                                "expected_value": false
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "is breastfeeding",
                            "criterion": "breastfeeding status",
                            "requirement": {
                                "requirement_type": "breastfeeding",
                                "expected_value": false
                            }
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "not_criteria": {
                                    "exact_snippets": "plans to breastfeed from the time of consent through 90 days after the last dose of study therapy",
                                    "criterion": "future breastfeeding plans",
                                    "requirement": {
                                        "requirement_type": "plans to breastfeed",
                                        "expected_value": false
                                    }
                                }
                            },
                            {
                                "not_criteria": {
                                    "exact_snippets": "plans to breastfeed from the time of consent through 90 days after the last dose of study therapy",
                                    "criterion": "future breastfeeding plans",
                                    "requirement": {
                                        "requirement_type": "time period",
                                        "expected_value": "from the time of consent through 90 days after the last dose of study therapy"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* History of prior allogeneic hematopoietic stem cell transplant",
                "criterions": [
                    {
                        "exact_snippets": "History of prior allogeneic hematopoietic stem cell transplant",
                        "criterion": "allogeneic hematopoietic stem cell transplant",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "History of prior allogeneic hematopoietic stem cell transplant",
                    "criterion": "allogeneic hematopoietic stem cell transplant",
                    "requirement": {
                        "requirement_type": "history",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Both moderate hepatic insufficiency AND moderate renal insufficiency:",
                "criterions": [
                    {
                        "exact_snippets": "moderate hepatic insufficiency",
                        "criterion": "hepatic insufficiency",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "moderate"
                        }
                    },
                    {
                        "exact_snippets": "moderate renal insufficiency",
                        "criterion": "renal insufficiency",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "moderate"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "moderate hepatic insufficiency",
                        "criterion": "hepatic insufficiency",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "moderate"
                        }
                    },
                    {
                        "exact_snippets": "moderate renal insufficiency",
                        "criterion": "renal insufficiency",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "moderate"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Famciclovir (at doses > 1500 mg PO per day)",
                "criterions": [
                    {
                        "exact_snippets": "Famciclovir (at doses > 1500 mg PO per day)",
                        "criterion": "Famciclovir dose",
                        "requirement": {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 1500,
                                "unit": "mg per day"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Famciclovir (at doses > 1500 mg PO per day)",
                        "criterion": "Famciclovir dose",
                        "requirement": {
                            "requirement_type": "route",
                            "expected_value": "PO"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Famciclovir (at doses > 1500 mg PO per day)",
                                "criterion": "Famciclovir dose",
                                "requirement": {
                                    "requirement_type": "dose",
                                    "expected_value": {
                                        "operator": ">",
                                        "value": 1500,
                                        "unit": "mg per day"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Famciclovir (at doses > 1500 mg PO per day)",
                                "criterion": "Famciclovir dose",
                                "requirement": {
                                    "requirement_type": "route",
                                    "expected_value": "PO"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Valacyclovir (at doses > 3000 mg PO per day)",
                "criterions": [
                    {
                        "exact_snippets": "Valacyclovir (at doses > 3000 mg PO per day)",
                        "criterion": "valacyclovir dose",
                        "requirement": {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 3000,
                                "unit": "mg per day"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Valacyclovir (at doses > 3000 mg PO per day)",
                    "criterion": "valacyclovir dose",
                    "requirement": {
                        "requirement_type": "dose",
                        "expected_value": {
                            "operator": ">",
                            "value": 3000,
                            "unit": "mg per day"
                        }
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Received any of the following within 30 days prior to enrollment",
                "criterions": [
                    {
                        "exact_snippets": "Received any of the following within 30 days prior to enrollment",
                        "criterion": "receipt of specified treatments or interventions",
                        "requirement": {
                            "requirement_type": "time since receipt",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Received any of the following within 30 days prior to enrollment",
                        "criterion": "receipt of specified treatments or interventions",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Received any of the following within 30 days prior to enrollment",
                                "criterion": "receipt of specified treatments or interventions",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Received any of the following within 30 days prior to enrollment",
                                "criterion": "receipt of specified treatments or interventions",
                                "requirement": {
                                    "requirement_type": "time since receipt",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 30,
                                        "unit": "days"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Human immunodeficiency virus (HIV) with CD4 count < 350. If HIV positive, must remain on antiretroviral therapy that is not anticipated to interact with letermovir throughout study",
                "criterions": [
                    {
                        "exact_snippets": "Human immunodeficiency virus (HIV)",
                        "criterion": "HIV infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "CD4 count < 350",
                        "criterion": "CD4 count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 350,
                                "unit": ""
                            }
                        }
                    },
                    {
                        "exact_snippets": "If HIV positive, must remain on antiretroviral therapy",
                        "criterion": "antiretroviral therapy",
                        "requirement": {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "antiretroviral therapy that is not anticipated to interact with letermovir throughout study",
                        "criterion": "antiretroviral therapy interaction with letermovir",
                        "requirement": {
                            "requirement_type": "interaction_with_letermovir",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Human immunodeficiency virus (HIV)",
                                "criterion": "HIV infection",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "CD4 count < 350",
                                "criterion": "CD4 count",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": "<",
                                        "value": 350,
                                        "unit": ""
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Human immunodeficiency virus (HIV)",
                                "criterion": "HIV infection",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "not_criteria": {
                                    "and_criteria": [
                                        {
                                            "exact_snippets": "If HIV positive, must remain on antiretroviral therapy",
                                            "criterion": "antiretroviral therapy",
                                            "requirement": {
                                                "requirement_type": "use",
                                                "expected_value": true
                                            }
                                        },
                                        {
                                            "exact_snippets": "antiretroviral therapy that is not anticipated to interact with letermovir throughout study",
                                            "criterion": "antiretroviral therapy interaction with letermovir",
                                            "requirement": {
                                                "requirement_type": "interaction_with_letermovir",
                                                "expected_value": false
                                            }
                                        }
                                    ]
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Previous participation in a study using letermovir",
                "criterions": [
                    {
                        "exact_snippets": "Previous participation in a study using letermovir",
                        "criterion": "previous participation in a study using letermovir",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Previous participation in a study using letermovir",
                    "criterion": "previous participation in a study using letermovir",
                    "requirement": {
                        "requirement_type": "history",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 5 times the upper limit of normal (ULN) or serum total bilirubin > 2.5 x ULN",
                "criterions": [
                    {
                        "exact_snippets": "Serum aspartate aminotransferase (AST) ... > 5 times the upper limit of normal (ULN)",
                        "criterion": "serum aspartate aminotransferase (AST)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 5,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "alanine aminotransferase (ALT) > 5 times the upper limit of normal (ULN)",
                        "criterion": "alanine aminotransferase (ALT)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 5,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "serum total bilirubin > 2.5 x ULN",
                        "criterion": "serum total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "Serum aspartate aminotransferase (AST) ... > 5 times the upper limit of normal (ULN)",
                                "criterion": "serum aspartate aminotransferase (AST)",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": ">",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "alanine aminotransferase (ALT) > 5 times the upper limit of normal (ULN)",
                                "criterion": "alanine aminotransferase (ALT)",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": ">",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "serum total bilirubin > 2.5 x ULN",
                        "criterion": "serum total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Hepatitis C if no prior or current curative antiviral therapy. For those currently on curative antiviral therapy, they will be allowed on trial if hepatitis C virus (HCV) quantitation is below the limit of detection and adequate liver function as above",
                "criterions": [
                    {
                        "exact_snippets": "Hepatitis C if no prior or current curative antiviral therapy",
                        "criterion": "hepatitis C infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Hepatitis C if no prior or current curative antiviral therapy",
                        "criterion": "hepatitis C infection",
                        "requirement": {
                            "requirement_type": "curative antiviral therapy history",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "currently on curative antiviral therapy ... hepatitis C virus (HCV) quantitation is below the limit of detection",
                        "criterion": "hepatitis C virus (HCV) quantitation",
                        "requirement": {
                            "requirement_type": "curative antiviral therapy status",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "currently on curative antiviral therapy ... hepatitis C virus (HCV) quantitation is below the limit of detection",
                        "criterion": "hepatitis C virus (HCV) quantitation",
                        "requirement": {
                            "requirement_type": "quantitation",
                            "expected_value": "below the limit of detection"
                        }
                    },
                    {
                        "exact_snippets": "currently on curative antiviral therapy ... adequate liver function as above",
                        "criterion": "liver function",
                        "requirement": {
                            "requirement_type": "curative antiviral therapy status",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "currently on curative antiviral therapy ... adequate liver function as above",
                        "criterion": "liver function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": "as above"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Hepatitis C if no prior or current curative antiviral therapy",
                                "criterion": "hepatitis C infection",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Hepatitis C if no prior or current curative antiviral therapy",
                                "criterion": "hepatitis C infection",
                                "requirement": {
                                    "requirement_type": "curative antiviral therapy history",
                                    "expected_value": false
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "currently on curative antiviral therapy ... hepatitis C virus (HCV) quantitation is below the limit of detection",
                                "criterion": "hepatitis C virus (HCV) quantitation",
                                "requirement": {
                                    "requirement_type": "curative antiviral therapy status",
                                    "expected_value": true
                                }
                            },
                            {
                                "or_criteria": [
                                    {
                                        "exact_snippets": "currently on curative antiviral therapy ... hepatitis C virus (HCV) quantitation is below the limit of detection",
                                        "criterion": "hepatitis C virus (HCV) quantitation",
                                        "requirement": {
                                            "requirement_type": "quantitation",
                                            "expected_value": "below the limit of detection"
                                        }
                                    },
                                    {
                                        "exact_snippets": "currently on curative antiviral therapy ... adequate liver function as above",
                                        "criterion": "liver function",
                                        "requirement": {
                                            "requirement_type": "curative antiviral therapy status",
                                            "expected_value": true
                                        }
                                    },
                                    {
                                        "exact_snippets": "currently on curative antiviral therapy ... adequate liver function as above",
                                        "criterion": "liver function",
                                        "requirement": {
                                            "requirement_type": "adequacy",
                                            "expected_value": "as above"
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "* Confirmed diagnosis of T-cell or B-cell prolymphocytic leukemia, chronic lymphocytic leukemia, peripheral T-cell lymphoma, cutaneous T-cell lymphoma, or Sezary syndrome",
                "criterions": [
                    {
                        "exact_snippets": "Confirmed diagnosis of T-cell or B-cell prolymphocytic leukemia",
                        "criterion": "T-cell prolymphocytic leukemia diagnosis",
                        "requirement": {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Confirmed diagnosis of T-cell or B-cell prolymphocytic leukemia",
                        "criterion": "B-cell prolymphocytic leukemia diagnosis",
                        "requirement": {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Confirmed diagnosis of ... chronic lymphocytic leukemia",
                        "criterion": "chronic lymphocytic leukemia diagnosis",
                        "requirement": {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Confirmed diagnosis of ... peripheral T-cell lymphoma",
                        "criterion": "peripheral T-cell lymphoma diagnosis",
                        "requirement": {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Confirmed diagnosis of ... cutaneous T-cell lymphoma",
                        "criterion": "cutaneous T-cell lymphoma diagnosis",
                        "requirement": {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Confirmed diagnosis of ... Sezary syndrome",
                        "criterion": "Sezary syndrome diagnosis",
                        "requirement": {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Confirmed seropositivity for CMV IgG (>= 0.7 U/mL) within 1 year of first letermovir dose",
                "criterions": [
                    {
                        "exact_snippets": "Confirmed seropositivity for CMV IgG (>= 0.7 U/mL)",
                        "criterion": "CMV IgG seropositivity",
                        "requirement": {
                            "requirement_type": "seropositivity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Confirmed seropositivity for CMV IgG (>= 0.7 U/mL)",
                        "criterion": "CMV IgG seropositivity",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.7,
                                "unit": "U/mL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "within 1 year of first letermovir dose",
                        "criterion": "CMV IgG test timing",
                        "requirement": {
                            "requirement_type": "time before first letermovir dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Intent to treat with alemtuzumab. Monotherapy or combination with chemotherapy is allowed",
                "criterions": [
                    {
                        "exact_snippets": "Intent to treat with alemtuzumab",
                        "criterion": "treatment intent with alemtuzumab",
                        "requirement": {
                            "requirement_type": "intent",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Monotherapy or combination with chemotherapy is allowed",
                        "criterion": "treatment regimen",
                        "requirement": {
                            "requirement_type": "allowed regimens",
                            "expected_value": [
                                "monotherapy",
                                "combination with chemotherapy"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Negative CMV IgM (< 30 AU/mL) within 7 days of first letermovir dose",
                "criterions": [
                    {
                        "exact_snippets": "Negative CMV IgM (< 30 AU/mL)",
                        "criterion": "CMV IgM",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 30,
                                "unit": "AU/mL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Negative CMV IgM (< 30 AU/mL)",
                        "criterion": "CMV IgM",
                        "requirement": {
                            "requirement_type": "qualitative result",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "within 7 days of first letermovir dose",
                        "criterion": "timing of CMV IgM test",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "within 7 days of first letermovir dose",
                        "criterion": "timing of CMV IgM test",
                        "requirement": {
                            "requirement_type": "reference event",
                            "expected_value": "first letermovir dose"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Able to provide informed consent",
                "criterions": [
                    {
                        "exact_snippets": "Able to provide informed consent",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "ability to provide",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Confirmed lack of active CMV infection as evidenced by:",
                "criterions": [
                    {
                        "exact_snippets": "Confirmed lack of active CMV infection",
                        "criterion": "active CMV infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Is 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy OR",
                "criterions": [
                    {
                        "exact_snippets": "6 weeks post-surgical bilateral oophorectomy",
                        "criterion": "time since bilateral oophorectomy",
                        "requirement": {
                            "requirement_type": "duration since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "with or without hysterectomy",
                        "criterion": "hysterectomy status",
                        "requirement": {
                            "requirement_type": "history of hysterectomy",
                            "expected_value": [
                                "with hysterectomy",
                                "without hysterectomy"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Eastern Cooperative Oncology Group (ECOG) performance status =< 3",
                "criterions": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status =< 3",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "N/A"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Microscopic documentation of azoospermia OR",
                "criterions": [
                    {
                        "exact_snippets": "Microscopic documentation of azoospermia",
                        "criterion": "azoospermia",
                        "requirement": {
                            "requirement_type": "documentation_method",
                            "expected_value": "microscopic"
                        }
                    },
                    {
                        "exact_snippets": "Microscopic documentation of azoospermia",
                        "criterion": "azoospermia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Highly unlikely to become pregnant or impregnate a partner by meeting at least one of the following:",
                "criterions": [
                    {
                        "exact_snippets": "Highly unlikely to become pregnant or impregnate a partner",
                        "criterion": "likelihood of pregnancy or impregnating a partner",
                        "requirement": {
                            "requirement_type": "likelihood",
                            "expected_value": "highly unlikely"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Has reached natural menopause (defined as 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone [FSH] levels in the postmenopausal range as determined by the local laboratory, or 12 months of spontaneous amenorrhea) OR",
                "criterions": [
                    {
                        "exact_snippets": "Has reached natural menopause (defined as 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone [FSH] levels in the postmenopausal range as determined by the local laboratory, or 12 months of spontaneous amenorrhea)",
                        "criterion": "menopausal status",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "natural menopause"
                        }
                    },
                    {
                        "exact_snippets": "6 months of spontaneous amenorrhea with serum follicle-stimulating hormone [FSH] levels in the postmenopausal range as determined by the local laboratory",
                        "criterion": "spontaneous amenorrhea duration",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "6 months of spontaneous amenorrhea with serum follicle-stimulating hormone [FSH] levels in the postmenopausal range as determined by the local laboratory",
                        "criterion": "serum follicle-stimulating hormone (FSH) level",
                        "requirement": {
                            "requirement_type": "range",
                            "expected_value": "postmenopausal range (per local laboratory)"
                        }
                    },
                    {
                        "exact_snippets": "12 months of spontaneous amenorrhea",
                        "criterion": "spontaneous amenorrhea duration",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Life expectancy > 4 months",
                "criterions": [
                    {
                        "exact_snippets": "Life expectancy > 4 months",
                        "criterion": "life expectancy",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 4,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Intrauterine device (IUD), diaphragm with spermicide, contraceptive sponge, condom, and vasectomy OR use of appropriate double barrier contraception. Hormonal contraceptives (e.g., birth control pills, transdermal patch, or injectables) are also acceptable",
                "criterions": [
                    {
                        "exact_snippets": "Intrauterine device (IUD), diaphragm with spermicide, contraceptive sponge, condom, and vasectomy OR use of appropriate double barrier contraception. Hormonal contraceptives (e.g., birth control pills, transdermal patch, or injectables) are also acceptable",
                        "criterion": "contraception method",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": [
                                "intrauterine device (IUD)",
                                "diaphragm with spermicide",
                                "contraceptive sponge",
                                "condom",
                                "vasectomy",
                                "appropriate double barrier contraception",
                                "hormonal contraceptives (e.g., birth control pills, transdermal patch, or injectables)"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Intrauterine device (IUD), diaphragm with spermicide, contraceptive sponge, condom, and vasectomy OR use of appropriate double barrier contraception. Hormonal contraceptives (e.g., birth control pills, transdermal patch, or injectables) are also acceptable",
                        "criterion": "contraception method",
                        "requirement": {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* A male or female subject who is of reproductive potential agrees to true abstinence or to use (or have their partner use) an acceptable method of birth control starting from the time of consent through 90 days after the last dose of study therapy. True abstinence is defined as abstinence in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., abstinence only on certain calendar days, abstinence only during ovulation period, use of symptothermal method, use of post-ovulation methods) and withdrawal are not acceptable methods of contraception. Acceptable methods of birth control are:",
                "criterions": [
                    {
                        "exact_snippets": "A male or female subject who is of reproductive potential",
                        "criterion": "reproductive potential",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "agrees to true abstinence or to use (or have their partner use) an acceptable method of birth control starting from the time of consent through 90 days after the last dose of study therapy",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "method",
                            "expected_value": [
                                "true abstinence",
                                "acceptable method of birth control"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "agrees to true abstinence or to use (or have their partner use) an acceptable method of birth control starting from the time of consent through 90 days after the last dose of study therapy",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "agrees to true abstinence or to use (or have their partner use) an acceptable method of birth control starting from the time of consent through 90 days after the last dose of study therapy",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": "from the time of consent through 90 days after the last dose of study therapy"
                        }
                    },
                    {
                        "exact_snippets": "True abstinence is defined as abstinence in line with the preferred and usual lifestyle of the subject",
                        "criterion": "true abstinence",
                        "requirement": {
                            "requirement_type": "definition",
                            "expected_value": "abstinence in line with the preferred and usual lifestyle of the subject"
                        }
                    },
                    {
                        "exact_snippets": "Periodic abstinence (e.g., abstinence only on certain calendar days, abstinence only during ovulation period, use of symptothermal method, use of post-ovulation methods) and withdrawal are not acceptable methods of contraception",
                        "criterion": "contraception method",
                        "requirement": {
                            "requirement_type": "unacceptable_methods",
                            "expected_value": [
                                "periodic abstinence",
                                "withdrawal",
                                "abstinence only on certain calendar days",
                                "abstinence only during ovulation period",
                                "use of symptothermal method",
                                "use of post-ovulation methods"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_exclusion": [
        {
            "identified_line": {
                "line": "* Note: Subjects who meet this exclusion criterion may, at the discretion of the investigator, have one repeat testing done. If the repeat value does not meet this criterion, they may continue in the screening process. Only the specific out of range value should be repeated (not the entire panel)",
                "criterions": [
                    {
                        "exact_snippets": "Subjects who meet this exclusion criterion",
                        "criterion": "exclusion criterion",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "condition": {
                            "exact_snippets": "Subjects who meet this exclusion criterion",
                            "criterion": "exclusion criterion",
                            "requirement": {
                                "requirement_type": "presence",
                                "expected_value": true
                            }
                        },
                        "then_criteria": {
                            "not_criteria": {
                                "exact_snippets": "If the repeat value does not meet this criterion, they may continue in the screening process.",
                                "criterion": "exclusion criterion (repeat value)",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": false
                                }
                            }
                        },
                        "else_criteria": null
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Suspected or known hypersensitivity to active or inactive ingredients of letermovir formulations",
                "criterions": [
                    {
                        "exact_snippets": "Suspected or known hypersensitivity to active or inactive ingredients of letermovir formulations",
                        "criterion": "hypersensitivity to letermovir ingredients",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Suspected or known hypersensitivity to active or inactive ingredients of letermovir formulations",
                        "criterion": "hypersensitivity to letermovir ingredients",
                        "requirement": {
                            "requirement_type": "certainty",
                            "expected_value": [
                                "suspected",
                                "known"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Hepatitis B surface antigen or core antibody positivity associated with detectable viral load. For any patient with serologic evidence of prior infection but undetectable viral load, viral load and surface antigen will be monitored every 2 weeks. Those with evidence of reactivation (detectable viral load) will be treated with entecavir or lamivudine. Upon resolution of detectable viral load, the patient will be allowed to continue on trial assuming adequate liver function as defined above. Alternatively, patients may be put on prophylactic entecavir or lamivudine to prevent hepatitis B reactivation at the investigator's discretion",
                "criterions": [
                    {
                        "exact_snippets": "Hepatitis B surface antigen or core antibody positivity associated with detectable viral load",
                        "criterion": "hepatitis B infection status",
                        "requirement": {
                            "requirement_type": "surface antigen positivity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Hepatitis B surface antigen or core antibody positivity associated with detectable viral load",
                        "criterion": "hepatitis B infection status",
                        "requirement": {
                            "requirement_type": "core antibody positivity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Hepatitis B surface antigen or core antibody positivity associated with detectable viral load",
                        "criterion": "hepatitis B infection status",
                        "requirement": {
                            "requirement_type": "viral load detectability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "serologic evidence of prior infection but undetectable viral load",
                        "criterion": "hepatitis B prior infection with undetectable viral load",
                        "requirement": {
                            "requirement_type": "prior infection (serologic evidence)",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "serologic evidence of prior infection but undetectable viral load",
                        "criterion": "hepatitis B prior infection with undetectable viral load",
                        "requirement": {
                            "requirement_type": "viral load detectability",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "evidence of reactivation (detectable viral load)",
                        "criterion": "hepatitis B reactivation",
                        "requirement": {
                            "requirement_type": "viral load detectability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Upon resolution of detectable viral load, the patient will be allowed to continue on trial assuming adequate liver function as defined above",
                        "criterion": "liver function",
                        "requirement": {
                            "requirement_type": "adequate liver function",
                            "expected_value": "as defined above"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "or_criteria": [
                                    {
                                        "exact_snippets": "Hepatitis B surface antigen or core antibody positivity associated with detectable viral load",
                                        "criterion": "hepatitis B infection status",
                                        "requirement": {
                                            "requirement_type": "surface antigen positivity",
                                            "expected_value": true
                                        }
                                    },
                                    {
                                        "exact_snippets": "Hepatitis B surface antigen or core antibody positivity associated with detectable viral load",
                                        "criterion": "hepatitis B infection status",
                                        "requirement": {
                                            "requirement_type": "core antibody positivity",
                                            "expected_value": true
                                        }
                                    }
                                ]
                            },
                            {
                                "exact_snippets": "Hepatitis B surface antigen or core antibody positivity associated with detectable viral load",
                                "criterion": "hepatitis B infection status",
                                "requirement": {
                                    "requirement_type": "viral load detectability",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "hepatitis B reactivation",
                                "criterion": "hepatitis B reactivation",
                                "requirement": {
                                    "requirement_type": "viral load detectability",
                                    "expected_value": true
                                }
                            },
                            {
                                "not_criteria": {
                                    "exact_snippets": "Upon resolution of detectable viral load, the patient will be allowed to continue on trial assuming adequate liver function as defined above",
                                    "criterion": "liver function",
                                    "requirement": {
                                        "requirement_type": "adequate liver function",
                                        "expected_value": "as defined above"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Has a history or current evidence of any condition, therapy, lab abnormality, or other circumstance that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or would be put at undue risk as judged by the investigator, such that it is not in the best interest of the subject to participate in this study",
                "criterions": [
                    {
                        "exact_snippets": "Has a history or current evidence of any condition, therapy, lab abnormality, or other circumstance that might confound the results of the study",
                        "criterion": "condition, therapy, lab abnormality, or other circumstance",
                        "requirement": {
                            "requirement_type": "potential to confound study results",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Has a history or current evidence of any condition, therapy, lab abnormality, or other circumstance that might ... interfere with the subject's participation for the full duration of the study",
                        "criterion": "condition, therapy, lab abnormality, or other circumstance",
                        "requirement": {
                            "requirement_type": "potential to interfere with participation for full duration",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Has a history or current evidence of any condition, therapy, lab abnormality, or other circumstance that ... would be put at undue risk as judged by the investigator, such that it is not in the best interest of the subject to participate in this study",
                        "criterion": "condition, therapy, lab abnormality, or other circumstance",
                        "requirement": {
                            "requirement_type": "potential to put subject at undue risk (as judged by investigator)",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Has a history or current evidence of any condition, therapy, lab abnormality, or other circumstance that ... would be put at undue risk as judged by the investigator, such that it is not in the best interest of the subject to participate in this study",
                        "criterion": "condition, therapy, lab abnormality, or other circumstance",
                        "requirement": {
                            "requirement_type": "not in the best interest of the subject to participate",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Has a history or current evidence of any condition, therapy, lab abnormality, or other circumstance that might confound the results of the study",
                        "criterion": "condition, therapy, lab abnormality, or other circumstance",
                        "requirement": {
                            "requirement_type": "potential to confound study results",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Has a history or current evidence of any condition, therapy, lab abnormality, or other circumstance that might ... interfere with the subject's participation for the full duration of the study",
                        "criterion": "condition, therapy, lab abnormality, or other circumstance",
                        "requirement": {
                            "requirement_type": "potential to interfere with participation for full duration",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Has a history or current evidence of any condition, therapy, lab abnormality, or other circumstance that ... would be put at undue risk as judged by the investigator, such that it is not in the best interest of the subject to participate in this study",
                        "criterion": "condition, therapy, lab abnormality, or other circumstance",
                        "requirement": {
                            "requirement_type": "potential to put subject at undue risk (as judged by investigator)",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Has a history or current evidence of any condition, therapy, lab abnormality, or other circumstance that ... would be put at undue risk as judged by the investigator, such that it is not in the best interest of the subject to participate in this study",
                        "criterion": "condition, therapy, lab abnormality, or other circumstance",
                        "requirement": {
                            "requirement_type": "not in the best interest of the subject to participate",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Currently participating or has participated in a study with an unapproved investigational compound or device within 28 days, or 5X half-life of the investigational compound (excluding monoclonal antibodies), whichever is longer, of initial dosing on this study. Subjects previously treated with a monoclonal antibody will be eligible to participate after a 28-day washout period",
                "criterions": [
                    {
                        "exact_snippets": "Currently participating or has participated in a study with an unapproved investigational compound or device within 28 days, or 5X half-life of the investigational compound (excluding monoclonal antibodies), whichever is longer, of initial dosing on this study.",
                        "criterion": "participation in a study with an unapproved investigational compound or device",
                        "requirement": {
                            "requirement_type": "time since last participation",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 28,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half-life of investigational compound (excluding monoclonal antibodies)"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Subjects previously treated with a monoclonal antibody will be eligible to participate after a 28-day washout period",
                        "criterion": "previous treatment with a monoclonal antibody",
                        "requirement": {
                            "requirement_type": "washout period",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Currently participating or has participated in a study with an unapproved investigational compound or device within 28 days, or 5X half-life of the investigational compound (excluding monoclonal antibodies), whichever is longer, of initial dosing on this study.",
                                "criterion": "participation in a study with an unapproved investigational compound or device",
                                "requirement": {
                                    "requirement_type": "time since last participation",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": ">=",
                                                "value": 28,
                                                "unit": "days"
                                            },
                                            {
                                                "operator": ">=",
                                                "value": 5,
                                                "unit": "half-life of investigational compound (excluding monoclonal antibodies)"
                                            }
                                        ]
                                    }
                                }
                            },
                            {
                                "not_criteria": {
                                    "exact_snippets": "Subjects previously treated with a monoclonal antibody will be eligible to participate after a 28-day washout period",
                                    "criterion": "previous treatment with a monoclonal antibody",
                                    "requirement": {
                                        "requirement_type": "washout period",
                                        "expected_value": {
                                            "operator": ">=",
                                            "value": 28,
                                            "unit": "days"
                                        }
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Subjects previously treated with a monoclonal antibody will be eligible to participate after a 28-day washout period",
                                "criterion": "previous treatment with a monoclonal antibody",
                                "requirement": {
                                    "requirement_type": "washout period",
                                    "expected_value": {
                                        "operator": "<",
                                        "value": 28,
                                        "unit": "days"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        }
    ],
    "failed_miscellaneous": []
}